Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis

Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis

(2012) Afsaneh Shirani et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cost-Effectiveness of Cardiac Resynchronization Therapy in the MADIT-CRT Trial

(2012) KATIA NOYES et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1

(2012) J. Jaime Caro et al.   VALUE IN HEALTH

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

(2012) Stephanie R. Earnshaw et al.   Applied Health Economics and Health Policy

Cost-effectiveness analyses of treatments for multiple sclerosis: Are they clinically relevant?

(2011) K. A. Smyth   NEUROLOGY

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study

(2011) K. Noyes et al.   NEUROLOGY

Costos de la Esclerosis Múltiple en Colombia

(2011) Martin Romero et al.   VALUE IN HEALTH

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis

(2011) Ken O’Day et al.   JOURNAL OF MEDICAL ECONOMICS

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective

(2010) Mark Nuijten et al.   CLINICAL THERAPEUTICS

Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis

(2010) Jessica Sharac et al.   DRUGS

Comprehensive Primary Care for Older Patients With Multiple Chronic Conditions

(2010) Chad Boult et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Does Medicare Have an Implicit Cost-Effectiveness Threshold?

(2010) James D. Chambers et al.   MEDICAL DECISION MAKING

Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials

(2010) C. Daniel Mullins et al.   PHARMACOECONOMICS

Using Comparative Effectiveness Research to Inform Policy and Practice in the UK NHS

(2010) Kalipso Chalkidou et al.   PHARMACOECONOMICS

Regulatory Benefit-Risk Assessment and Comparative Effectiveness Research

(2010) Louis P. Garrison   PHARMACOECONOMICS

Perspective and Desire in Comparative Effectiveness Research

(2010) Anthony J. Culyer   PHARMACOECONOMICS

Managed Care Pharmacy Sees Potential of Comparative Effectiveness Research to Improve Patient Care and Lower Costs

(2010) Judith Cahill et al.   PHARMACOECONOMICS

An Analysis of NICEʼs ‘Restricted’ (or ‘Optimized’) Decisions

(2010) Phill OʼNeill et al.   PHARMACOECONOMICS

The Economics of Comparative Effectiveness Studies

(2010) David Meltzer et al.   PHARMACOECONOMICS

The Value of Value of Information

(2010) Simon Eckermann et al.   PHARMACOECONOMICS

International Comparison of Comparative Effectiveness Research in Five Jurisdictions

(2010) Adrian R. Levy et al.   PHARMACOECONOMICS

Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition

(2010) Slobodan Jankovic et al.   Vojnosanitetski Pregled

Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis

(2009) Evelyn Chiao et al.   CURRENT MEDICAL RESEARCH AND OPINION

What can be learned from open direct comparative trials in multiple sclerosis?

(2009) Omar Khan   JOURNAL OF THE NEUROLOGICAL SCIENCES

The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions

(2009) G Kobelt et al.   Multiple Sclerosis Journal

Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy

(2009) Patricia K Coyle et al.   Multiple Sclerosis Journal

The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?

(2009) E. C. Klawiter et al.   NEUROLOGY

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

(2009) Ray Gani et al.   PHARMACOECONOMICS

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a

(2009) Shien Guo et al.   PHARMACOECONOMICS

Utilities of the EQ-5D

(2009) Saskia Knies et al.   PHARMACOECONOMICS

Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

(2009) Paul Tappenden et al.   VALUE IN HEALTH

International Comparisons in Valuing EQ-5D Health States: A Review and Analysis

(2009) Richard Norman et al.   VALUE IN HEALTH

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study

(2008) S Minden et al.   Multiple Sclerosis Journal

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden

(2008) G Kobelt et al.   Multiple Sclerosis Journal

Quantitative risk-benefit analysis of natalizumab

(2008) J. P. Thompson et al.   NEUROLOGY